SKP Financial Share News Feed - London South East

BRIEF-Skyepharma - Revenues show strong growth

Mon, 27 Oct 2008 07:31:23 GMT

LONDON, Oct 27 (Reuters) - SkyePharma PLC: * Revenues since July 1, continue to show significant growth compared with

BRIEF-SkyePharma successfully completes Flutiform U.S. trials

Thu, 23 Oct 2008 06:29:37 GMT

LONDON, Oct 23 (Reuters) - SkyePharma PLC: * Successful completion of Flutiform U.S. clinical trial programme

Skyepharma says bond proposals, placing, open offer seen finalised on Sept. 25

Tue, 23 Sep 2008 14:55:42 GMT

LONDON (Thomson Financial) - Specialist British drug delivery company Skyepharma Plc. said it expects its bond proposals, placing and open offer to be finalised on Sept 25.

STOCKS NEWS EUROPE-UK small cap index stay flat

Thu, 04 Sep 2008 08:14:50 GMT

Sept 4 (Reuters) - STOCKS NEWS Reuters Results diary Stocks on the move [HOT-RTRS] Real-time Equity News [E] [WEU/EQUITY]

CORRECTED-STOCKS NEWS EUROPE-UK small caps fall 0.2%

Thu, 04 Sep 2008 07:17:02 GMT

Sept 4 (Reuters) - (Corrects comparison to show pan-European small caps underperformed the large caps)

UPDATE 1-SkyePharma sets new terms for convertibles

Mon, 01 Sep 2008 18:19:50 GMT

LONDON, Sept 1 (Reuters) - Specialist British drug delivery company SkyePharma Plc announced plans to change the terms and conditions on two of its convertible bonds and raise 18.4 million pounds ($33 million) by selling new shares.

BRIEF-SkyePharma in 18.4 mln stg placing and open offer

Mon, 01 Sep 2008 17:54:35 GMT

LONDON, Sept 1 (Reuters) - SkyePharma Plc : * Announces proposals for renegotiated terms for the 2024 and 2025 convertible bonds, extending put dates to 2013 and 2014 respectively and resetting the conversion price

SkyePharma bond renegotiation deal seen 'this week'

Mon, 01 Sep 2008 09:12:18 GMT

LONDON, Sept 1 (Reuters) - Specialist drug delivery company SkyePharma Plc is set to announce a renegotiation of its convertible bonds this week, according to two analysts who cover the sector.

UPDATE 1-SkyePharma shares surge on hopes for bonds deal

Thu, 28 Aug 2008 08:05:27 GMT

LONDON, Aug 28 (Reuters) - Britain's Skyepharma Plc , a specialist in drug delivery technology, said on Thursday it was close to a deal on renegotiating its convertible bonds, sending the company's shares 20 percent higher.

BRIEF-Skyepharma H1 pretax loss 6.4 mln pounds

Thu, 28 Aug 2008 08:04:08 GMT

LONDON, Aug 28 (Reuters) - Skyepharma Plc : * H1 pretax loss 6.4 million pounds versus 14.1 million, sales 28.4 million

Skyepharma partner completes two Phase III studies for Flutiform in EU programme

Tue, 22 Jul 2008 06:38:44 GMT

LONDON (Thomson Financial) - SkyePharma Plc, the drug delivery specialist, says its European development partner Mundipharma has recorded positive results and successfully completed two Phase III clinical studies for the European development programme for Flutiform, its development asthma prod

Skyepharma eyes debt swap - report

Sun, 13 Jul 2008 13:46:19 GMT

LONDON (Thomson Financial) - Biotech company Skyepharma is in talks with its backers about conducting a debt-for-equity swap on 89 million pounds of bonds due to mature over the next two years, the Sunday Telegraph reported.

SkyePharma blames market conditions for lack of agreement on refinancing UPDATE

Tue, 08 Jul 2008 09:28:56 GMT

(Adds analyst, company comment) LONDON (Thomson Financial) - SkyePharma Plc, the embattled UK-biotech, said conditions in the capital markets have halted talks with key bondholders and investors about a specific proposal to refinance the company's 89 million pounds of convertible bonds and

UK smallcap opening - SkyePharma lower after financing talks hit snag

Tue, 08 Jul 2008 07:23:59 GMT

LONDON (Thomson Financial) - SkyePharma was 0.73 pence lower at 4.75 pence in early deals after the biotech company said conditions in the capital markets have led to a halt in talks with key bondholders and investors about a specific proposal to refinance the company's 89 million pounds of co

SkyePharma blames market conditions for lack of agreement on refinancing bonds

Tue, 08 Jul 2008 06:56:49 GMT

LONDON (Thomson Financial) - SkyePharma Plc, the embattled UK-biotech, said conditions in the capital markets have halted talks with key bondholders and investors about a specific proposal to refinance the company's 89 million pounds of convertible bonds and that an alternative plan is now bei

SkyePharma trumpets third Flutiform Phase III efficacy trial success

Thu, 03 Jul 2008 06:59:14 GMT

LONDON (Thomson Financial) - SkyePharma Plc. said its third Flutiform Phase III efficacy study, for the treatment of mild to moderate asthma in adolescent and adult patients, has been successful in the third of several clinical efficacy studies being carried out in preparation for U.S. regulat

SkyePharma says second set of Flutiform phase III trial results successful

Tue, 17 Jun 2008 06:38:08 GMT

LONDON (Thomson Financial) - SkyePharma Plc., said its second Phase III efficacy study for its Flutiform asthma treatment has successfully met its endpoints and furthers the product's progress towards its regulatory filing with the U.S. Food and Drug Administration.

SkyePharma single digit royalties on GSK's U.S. Requip XL approval UPDATE

Mon, 16 Jun 2008 08:34:51 GMT

LONDON (Thomson Financial) - British drug delivery specialist SkyePharma Plc has announced that it is in line for low-to mid-single digit royalties after development partner GlaxoSmithKline Plc announced on Friday that U.S. authorities have given approval for its Requip XL Parkinson's Disease

SkyePharma low to mid single digit royalties on GSK's US Requip XL approval

Mon, 16 Jun 2008 06:38:43 GMT

LONDON (Thomson Financial) - British drug delivery specialist SkyePharma Plc has announced that it is in line for low-to mid-single digit royalties after development partner GlaxoSmithKline Plc announced on Friday that US authorities have given approval for its Requip XL Parkinson's Disease dr

Skyepharma says CEO Condella will step down, COO Cunningham to replace

Wed, 21 May 2008 07:25:08 GMT

LONDON (Thomson Financial) - Skyepharma Plc. said chief executive Frank Condella will step down once the company has completed its financial restructuring by refinancing or renegotiating its convertible bonds.

Skyepharma says results from phase III Flutiform work still encouraging

Tue, 20 May 2008 07:03:29 GMT

LONDON (Thomson Financial) - Drug delivery specialist Skyepharma Plc. said results form its Phase III, long-term, open label safety study evaluating Flutiform for the treatment of asthma in adolescent and adult patients, continue to be encouraging.

Skyepharma says revenues in the first quarter encouraging

Mon, 19 May 2008 07:08:17 GMT

LONDON (Thomson Financial) - SkyePharma Plc. said it has made an encouraging start to the year with encouraging revenues in the first quarter.

SkyePharma says phase III efficacy Flutiform study meets goals UPDATE

Wed, 30 Apr 2008 09:10:43 GMT

(Adds analyst reaction, company comments) LONDON (Thomson Financial) - Drug delivery specialist SkyePharma Plc. said a late-stage study of its asthma treatment Flutiform has met its goals, taking the company a step nearer to regulatory filing in the United States.

SkyePharma says a phase III efficacy Flutiform study meets goals UPDATE

Wed, 30 Apr 2008 06:53:21 GMT

(Adds details from statement) LONDON (Thomson Financial) - Drug delivery specialist SkyePharma Plc. says that a late-stage study of its asthma treatment Flutiform has met its goals, taking the company a step nearer to regulatory filing in the United States.

SkyePharma says a phase III efficacy Flutiform study meets goals

Wed, 30 Apr 2008 06:28:34 GMT

LONDON (Thomson Financial) - Drug delivery specialist SkyePharma plc says that a late-stage study of its asthma treatment Flutiform has met its goals, taking the company a step nearer to regulatory filing in the US.

SkyePharma agrees Flutiform exclusive licence deal with Kyorin in Japan UPDATE

Tue, 22 Apr 2008 09:06:07 GMT

(Adds CEO comments, analyst reaction, live share price) LONDON (Thomson Financial) - SkyePharma plc. has signed an exclusive development, distribution and license agreement with Kyorin Pharmaceutical Co., Ltd., a unit of Kyorin Co. Ltd, for its lead product, the asthma treatment Flutiform.

SkyePharma agrees Flutiform exclusive licence deal with Kyorin in japan

Tue, 22 Apr 2008 06:47:09 GMT

LONDON (Thomson Financial) - SkyePharma plc. has signed an exclusive development, distribution and license agreement with Kyorin Pharmaceutical Co., Ltd., a unit of Kyorin Co. Ltd, for its lead product, the asthma treatment Flutiform.

SkyePharma reveals positive Flutiform results from paediatric study UPDATE

Tue, 15 Apr 2008 10:32:31 GMT

(adds detail, CEO, analyst comment) LONDON (Thomson Financial) - UK pharmaceutical group SkyePharma Plc. announced positive results for its asthma drug Flutiform after a paediatric study.

SkyePharma reveals positive Flutiform results from paediatric study

Tue, 15 Apr 2008 07:10:20 GMT

LONDON (Thomson Financial) - UK pharmaceutical group SkyePharma Plc. announced positive results for its asthma drug Flutiform after a paediatric study.

SkyePharma FY pretax loss 23.7 mln stg, renegotiate bonds by year end UPDATE

Thu, 27 Mar 2008 10:10:43 GMT

(Recasts, adds company comment) LONDON (Thomson Financial) - UK drug delivery specialist SkyePharma said it would like to complete renegotiation of its convertible bonds by the end of this year, as it reported a wider full-year pretax loss of 23.7 mln stg against 19.3 mln the year before,

SkyePharma FY pretax loss 23.7 mln stg, goal to renegotiate bonds UPDATE

Thu, 27 Mar 2008 08:43:41 GMT

(Adds initial analyst comment) LONDON (Thomson Financial) - UK drug delivery specialist SkyePharma says that pretax loss for the full year widened to 23.7 mln stg vs 19.3 mln, mainly due to R&D expenses associated with the continuing development of its asthma product Flutiform.

Skyepharma FY pretax loss 23.7 mln stg vs 19.3 mln, goal to renegotiate bonds

Thu, 27 Mar 2008 07:43:10 GMT

LONDON (Thomson Financial) - UK drug delivery specialist SkyePharma says that pretax loss for the full year widened to 23.7 mln stg vs 19.3 mln, mainly due to R&D expenses associated with the continuing development of its asthma product Flutiform.

Skyepharma in collaboration with Dr Reddy's Labs for drug delivery system study

Fri, 08 Feb 2008 08:03:27 GMT

LONDON (Thomson Financial) - Skyepharma PLC said it entered into an agreement with India's Dr Reddy's Laboratories for a feasibility study of a product utilizing two of its proprietary drug delivery systems.

Glaxosmithkline's Requip XL delayed again by FDA to consider new information

Tue, 05 Feb 2008 07:35:54 GMT

LONDON (Thomson Financial) - GlaxoSmithKline PLC's Requip XL has been delayed again by the FDA because the regulatory agency said it needs more time to consider new information presented by the drugmaker.

Sciele Pharma receives approval for new formulation for blood pressure drug

Thu, 03 Jan 2008 15:58:18 GMT

NEW YORK (Thomson Financial) - Shares of Sciele Pharma Inc. rose Thursday after the company said it had received approval from the Food and Drug Administration for all four dosage strengths of a new formulation of its drug Sular, which treats high blood pressure.

SkyePharma to receive 2 mln usd and royalties after US Sular approval

Thu, 03 Jan 2008 09:08:40 GMT

LONDON (Thomson Financial) - UK-based SkyePharma has announced that it is to receive a 2 mln usd payment and 'low single digit' royalties after the US Food and Drug Administration approved yesterday four dosage strengths of a new formulation of Sciele Pharma's high blood pressure treatment Sul

UK smallcap opening - SkyePharma gains after receiving FDA approval for Sular

Thu, 03 Jan 2008 09:01:43 GMT

LONDON (Thomson Financial) - Shares in SkyePharma were 0-3/4 pence higher at 13-1/4 by 8.43 am after the pharmaceutical company announced it has received regulatory approval from the US Food and Drug Administration (FDA) for all four dosage strengths of its new Sular formulation, which treats

SkyePharma says Abbott meets extra US costs for Flutiform UPDATE

Thu, 20 Dec 2007 08:43:37 GMT

(Adds analyst comment, background) LONDON (Thomson Financial) - SkyePharma PLC says it has revised the agreement with Abbott for the development and commercialisation in the United States of its asthma drug Flutiform.

SkyePharma to accept less milestones as Abbott meets more US costs for Flutiform

Thu, 20 Dec 2007 08:20:26 GMT

LONDON (Thomson Financial) - SkyePharma PLC says it has revised the agreement with Abbott for the development and commercialisation in the United States of its asthma drug Flutiform.

CORRECTION SkyePharma completes enrolment in Flutiform efficacy trials

Tue, 18 Dec 2007 11:06:11 GMT

(Corrects that the recruitment is for the Phase III efficacy trials, not for the supplemental efficacy studies requested by the FDA. Headline, 1st and 2nd paragraphs have been corrected, and last paragraph removed)

SkyePharma completes enrolment in Flutiform further efficacy trials for FDA NDA

Tue, 18 Dec 2007 08:21:10 GMT

LONDON (Thomson Financial) - SkyePharma has completed enrolment in the further efficacy trials that were requested by the Food and Drug Administration (FDA) before it files a New Drug Application (NDA) for its asthma treatment Flutiform.

UK small caps close lower; Centurion Electronics dives on funding worries

Mon, 10 Dec 2007 17:31:47 GMT

LONDON (Thomson Financial) - UK small caps fell, but closed off session lows, as the wider market finished in positive territory, with Centurion Electronics losing half its value after warning it will have to raise more money.

SkyePharma says FDA gives approvable letter for GlaxoSmithKline's Requip XL

Mon, 10 Dec 2007 14:31:39 GMT

LONDON (Thomson Financial) - SkyePharma has announced that the US Food and Drug Administration has issued an approvable letter for GlaxoSmithKline's Requip XL extended release Parkinson's disease tablets, meaning that the tablets can be approved as long as certain conditions are met.

SkyePharma says FDA extends PDUFA date on new Sular formulation to Jan 2 UPDATE

Mon, 05 Nov 2007 14:56:42 GMT

(adds company comment) LONDON (Thomson Financial) - SkyePharma said that Sciele Pharma's new Sular formulation, which was filed as a supplemental New Drug Application (sNDA) in June with the US Food & Drug Administration (FDA), has had its Pharmacy Drug User Fee Act (PDUFA) date extended t

Skyepharma says FDA extends PDUFA date on new Sular formulation to Jan 2, 2008

Mon, 05 Nov 2007 14:42:08 GMT

LONDON (Thomson Financial) - SkyePharma said that Sciele Pharma's new Sular formulation, which was filed as a supplemental New Drug Application (sNDA) in June with the US Food & Drug Administration (FDA), has had its Pharmacy Drug User Fee Act (PDUFA) date extended to Jan 2, 2008 from Nov 2, 2

Skyepharma completes successful Phase III trial for Flutiform asthma drug

Fri, 02 Nov 2007 07:36:11 GMT

LONDON (Thomson Financial) - Skyepharma PLC said it has completed a successful Phase III trial for its asthma medicine Flutiform, and it expects to apply for US Food and Drug Administration approval in the second half of 2008.

NOTE TO SUBSCRIBERS: Skyepharma, GSK, Mylan

Tue, 23 Oct 2007 14:01:50 GMT

LONDON (Thomson Financial) - -Please ignore two flashes transmitted at 1401 BST and 1402 BST: *SKYEPHARMA SAYS AGREES PATENT LICENCE WITH GSK AND MYLAN ON GENERIC LAUNCH

Skyepharma appoints Jeremy Scudamore as its new non-exec chairman

Tue, 09 Oct 2007 14:15:22 GMT

LONDON (Thomson Financial) - Skyepharma PLC said it has appointed Jeremy Scudamore as its new non-executive chairman, with effect from Oct 15, replacing Jerry Karabelas.

SkyePharma launches extended-release zileuton asthma drug ZYFLO in US

Thu, 27 Sep 2007 13:23:52 GMT

LONDON (Thomson Financial) - SkyePharma PLC and its US marketing partner, Critical Therapeutics Inc have announced the US launch of ZYFLO CR, the extended-release zileuton tablets for the prevention and treatment of asthma.

Skyepharma H1 pretax loss narrows; sees H2 sales similar to H1 UPDATE

Thu, 20 Sep 2007 08:45:36 GMT

(Updates with expenses and outlook details) LONDON (Thomson Financial) - Skyepharma PLC reported a narrower first-half pretax loss on lower expenses, and said it continues to have confidence in the potential for significant growth. It also reiterated its target to move into profit in 2009.